What is Tyra Biosciences, Inc.'s stock issuance proceeds?

Tyra Biosciences, Inc. (TYRA) reported stock issuance proceeds of $147.85M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Tyra Biosciences, Inc. TYRA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

IncyteINCY

$97.93M+2,923%

UroGen PharmaURGN

$0-100%

BridgeBio PharmaBBIO

$22.59M—

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

Nuvation BioNUVB

$908K-16.1%

Arcus BiosciencesRCUS

$0-100%

Other financials

Income statement

See full

Operating income-$42.0M-31.9%

Net income-$39.3M-39.6%

EPS (diluted)-$0.64-36.2%

Balance sheet

See full

Cash & equivalents$85.0M-15.7%

Total debt$5.7M-6.9%

Total equity$387.6M+19.8%

Total assets$412.0M+20.0%

Cash flow

See full

Operating cash flow-$32.6M-27.9%

CapEx$88.0K+529%

Free cash flow-$32.7M-28.2%

Valuation

See full

Market cap$1.81B+318%

Enterprise value$1.73B+397%

Returns & leverage

See full

Return on equity-36.9%+21.1pp

Debt / equity0×0.0×

Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s stock issuance proceeds?: Tyra Biosciences, Inc. (TYRA) reported stock issuance proceeds of $147.85M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.